Treatment

Personalized approach to dementia prevention and treatment

The Phase III NILEAD trial: nilotinib as a novel treatment for AD

The future of SAGE-718 in Alzheimer’s disease treatment

The impact of TKIs on miRNA expression in the treatment of AD

Insights into the upcoming LIGHTWAVE trial using SAGE-718 to treat patients with MCI and early AD

The COCOA Trial: can multimodal lifestyle interventions treat AD?

New mechanisms to treat Alzheimer’s disease by targeting the NMDA pathway

Long-term transdermal nicotine for the treatment of mild cognitive impairment

The PreventE4 study: testing omega-3 supplementation in APOE4 carriers before the onset of dementia

Phase II clinical trial of SAGE-718 for the treatment of MCI and early AD

Phase II trial of XPro1595 for the treatment of Alzheimer’s disease

Viral-mediated gene therapy for neurodegenerative disease

Improving the precision and safety of CRISPR/Cas genome editing

EXERT: why was strength/balance training as effective as cardio in preventing cognitive decline?

How does exercise affect cognition?

The neurogenesis hypothesis: NA-831 for the treatment of Alzheimer’s disease